R&D News | pharmaphorum

News

Sanofi partners J&J on E. coli vaccine

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus

News

Exscientia trims pipeline to focus on top cancer prospects

UK biotech Exscientia has tapped the brakes on the rapid expansion of its R&D pipeline, narrowing its in-house activities to oncology programmes that it says offer the

News

mRNA scientists share Nobel prize for medicine

Katalin Karikó and Drew Weissman of the University of Pennsylvania have jointly won the 2023 Nobel Prize in Physiology or Medicine for discoveries that enabled the develop

News

Novartis adds another string to iptacopan’s bow

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by

News

Aviva backs £1bn cancer hub in London

A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde

News

Biogen shuts digital health unit and exits Apple alliance

Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.

Sanofi partners J&J on E. coli vaccine

Exscientia trims pipeline to focus on top cancer prospects

mRNA scientists share Nobel prize for medicine

Novartis adds another string to iptacopan’s bow

Aviva backs £1bn cancer hub in London

Biogen shuts digital health unit and exits Apple alliance

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks